You are here

Article Text

Article menu
Download PDFPDF
Aetiology
Cohort study
Metoclopramide in pregnancy: no association with adverse fetal and neonatal outcomes
  1. Ilan Matok,
  2. Amichai Perlman
  1. Faculty of Medicine, Division of Clinical Pharmacy, School of Pharmacy, The Hebrew University of Jerusalem, Jerusalem, Israel
  1. Correspondence to : Dr Ilan Matok, Division of Clinical Pharmacy, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, PO Box 12065, Jerusalem 9112001, Israel; ilanma{at}ekmd.huji.ac.il

https://doi.org/10.1136/eb-2013-101654

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Commentary on: Pasternak B, Svanström H, Mølgaard-Nielsen D, et al. Metoclopramide in pregnancy and risk of major congenital malformations and fetal death. JAMA 2013;310:1601–11.OpenUrlCrossRefPubMedWeb of Science

    Context

    Nausea and vomiting of pregnancy (NVP) affects as many as 50–80% of pregnant women during the first trimester.1 NVP can cause considerable physical and psychological distress, can often be debilitating and sometimes requires hospitalisation. In addition to rehydration and various dietary recommendations, treatment of NVP often requires pharmacological interventions, such as an antihistamine combined with pyridoxine, 5-HT3 antagonist or dopamine antagonist. Despite their widespread use, data regarding the safety of many of these agents in pregnancy are limited, due to the exclusion of pregnant women from clinical …

    View Full Text

    Footnotes

    • Correction notice This article has been corrected since it was published Online First. The last sentence has been amended and reference 5 deleted.

    • Competing interests None.